1
|
Skaff Y, Jarrah M, Filippaios A, Sharkawi MA, Mehawej J. Emphysematous pancreatitis with pulmonary embolism: A case report. Respir Med Case Rep 2023; 42:101813. [PMID: 36691653 PMCID: PMC9860406 DOI: 10.1016/j.rmcr.2023.101813] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2022] [Revised: 10/01/2022] [Accepted: 01/13/2023] [Indexed: 01/18/2023] Open
Abstract
Background Emphysematous pancreatitis is a severe systemic inflammatory process with reports of pulmonary embolism in the setting of acute pancreatitis rarely described. Case presentation A 61-year-old woman presented with severe abdominal pain of 1 day duration. She was found to have acute interstitial pancreatitis. During her hospitalization, the patient developed worsening abdominal pain associated with increasing oxygen demands, requiring supplemental oxygen through nasal cannula. Workup showed pulmonary embolism in the posterior segmental branch of the left lower lobar artery and development of emphysematous pancreatitis was noted on imaging. The patient was started on intravenous antibiotics and therapeutic anticoagulation; her condition improved and was discharged home. Conclusion Patients with severe acute pancreatitis may be at risk for pulmonary embolism due to immobilization and other inflammatory mechanisms. Mitigating individualized risk factors and anticoagulation use as prophylaxis should be considered in patients with pancreatitis to prevent embolism. Early detection by clinicians is critical to reduce misdiagnosis and mortality rates.
Collapse
Affiliation(s)
- Yara Skaff
- Division of Internal Medicine, Department of Medicine, Lebanese American University Medical Center Rizk Hospital, Beirut, Lebanon
| | - Mohammad Jarrah
- Division of Internal Medicine, Department of Medicine, Lebanese American University Medical Center Rizk Hospital, Beirut, Lebanon
| | - Andreas Filippaios
- Department of Medicine, University of Massachusetts Chan Medical School, MA, USA,Corresponding author. Department of Medicine, University of Massachusetts Chan Medical School, 55 Lake Avenue North, Worcester, MA, 01655, USA.
| | - Musa A. Sharkawi
- Division of Cardiology, Department of Medicine, Augusta University Medical Center, GA, USA
| | - Jordy Mehawej
- Department of Medicine, University of Massachusetts Chan Medical School, MA, USA
| |
Collapse
|
2
|
Patel B, Sharkawi MA, Shah PB. Recurrent Paravalvular Leak Following Mitral Valve Replacement. JAMA Cardiol 2021; 6:e213737. [PMID: 34902000 DOI: 10.1001/jamacardio.2021.3737] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Affiliation(s)
- Badar Patel
- Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
| | - Musa A Sharkawi
- Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
| | - Pinak B Shah
- Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
| |
Collapse
|
3
|
Habertheuer A, Harloff MT, Sharkawi MA, Sobieszczyk PS, Sabe AA, Shah PB, Kaneko T. Transcatheter valve implantation in a failed homograft. Ann Cardiothorac Surg 2021; 10:717-719. [PMID: 34733706 DOI: 10.21037/acs-2021-tviv-18] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2021] [Accepted: 08/09/2021] [Indexed: 11/06/2022]
Affiliation(s)
- Andreas Habertheuer
- Division of Cardiac Surgery, Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA
| | - Morgan T Harloff
- Division of Cardiac Surgery, Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA
| | - Musa A Sharkawi
- Division of Cardiology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA
| | - Piotr S Sobieszczyk
- Division of Cardiology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA
| | - Ashraf A Sabe
- Division of Cardiac Surgery, Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA
| | - Pinak B Shah
- Division of Cardiology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA
| | - Tsuyoshi Kaneko
- Division of Cardiac Surgery, Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA
| |
Collapse
|
4
|
Sung JG, Sharkawi MA, Shah PB, Croce KJ, Bergmark BA. Integrating Intracoronary Imaging into PCI Workflow and Catheterization Laboratory Culture. Curr Cardiovasc Imaging Rep 2021. [DOI: 10.1007/s12410-021-09556-4] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
|
5
|
Varshney AS, Wang DE, Bhatt AS, Blood A, Sharkawi MA, Siddiqi HK, Vaduganathan M, Monteleone PP, Patel MR, Jones WS, Lopes RD, Mehra MR, Bhatt DL, Kochar A. Characteristics of clinical trials evaluating cardiovascular therapies for Coronavirus Disease 2019 Registered on ClinicalTrials.gov: a cross sectional analysis. Am Heart J 2021; 232:105-115. [PMID: 33121978 PMCID: PMC7586939 DOI: 10.1016/j.ahj.2020.10.065] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/15/2020] [Accepted: 10/21/2020] [Indexed: 12/26/2022]
Abstract
Morbidity and mortality associated with COVID-19 has increased exponentially, and patients with cardiovascular (CV) disease are at risk for poor outcomes. Several lines of evidence suggest a potential role for CV therapies in COVID-19 treatment. Characteristics of clinical trials of CV therapies related to COVID-19 registered on ClinicalTrials.gov have not been described. METHODS ClinicalTrials.gov was queried on August 7, 2020 for COVID-19 related trials. Studies evaluating established CV drugs, other fibrinolytics (defibrotide), and extracorporeal membrane oxygenation were included. Studies evaluating anti-microbial, convalescent plasma, non-colchicine anti-inflammatory, and other therapies were excluded. Trial characteristics were tabulated from study-specific entries. RESULTS A total of 2,935 studies related to COVID-19 were registered as of August 7, 2020. Of these, 1,645 were interventional studies, and the final analytic cohort consisted of 114 studies evaluating 10 CV therapeutic categories. Antithrombotics (32.5%; n = 37) were most commonly evaluated, followed by pulmonary vasodilators (14.0%; n = 16), renin-angiotensin-aldosterone system-related therapies (12.3%; n = 14), and colchicine (8.8%; n = 10). Trials evaluating multiple CV therapy categories and CV therapies in combination with non-CV therapies encompassed 4.4% (n = 5) and 9.6% (n = 11) of studies, respectively. Most studies were designed for randomized allocation (87.7%; n = 100), enrollment of less than 1000 participants (86.8%; n = 99), single site implementation (55.3%; n = 63), and had a primary outcome of mortality or a composite including mortality (56.1%; n = 64). Most study populations consisted of patients hospitalized with COVID-19 (81.6%; n = 93). At the time of database query, 28.9% (n = 33) of studies were not yet recruiting and the majority were estimated to be completed after December 2020 (67.8%; n = 78). Most lead sponsors were located in North America (43.9%; n = 50) or Europe (36.0%; n = 41). CONCLUSIONS A minority (7%) of clinical trials related to COVID-19 registered on ClinicalTrials.gov plan to evaluate CV therapies. Of CV therapy studies, most were planned to be single center, enroll less than 1000 inpatients, sponsored by European or North American academic institutions, and estimated to complete after December 2020. Collectively, these findings underscore the need for a network of sites with a platform protocol for rapid evaluation of multiple therapies and generalizability to inform clinical care and health policy for COVID-19 moving forward.
Collapse
Affiliation(s)
- Anubodh S. Varshney
- Brigham and Women’s Hospital Heart & Vascular Center and Harvard Medical School, Boston, MA,Reprint requests: Anubodh S. Varshney, MD, Brigham and Women's Hospital, Division of Cardiovascular Medicine, 70 Francis St, Boston, MA 02115
| | - David E. Wang
- Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA
| | - Ankeet S. Bhatt
- Brigham and Women’s Hospital Heart & Vascular Center and Harvard Medical School, Boston, MA
| | - Alexander Blood
- Brigham and Women’s Hospital Heart & Vascular Center and Harvard Medical School, Boston, MA
| | - Musa A. Sharkawi
- Brigham and Women’s Hospital Heart & Vascular Center and Harvard Medical School, Boston, MA
| | - Hasan K. Siddiqi
- Brigham and Women’s Hospital Heart & Vascular Center and Harvard Medical School, Boston, MA
| | - Muthiah Vaduganathan
- Brigham and Women’s Hospital Heart & Vascular Center and Harvard Medical School, Boston, MA
| | - Peter P. Monteleone
- Seton Heart Institute, The University of Texas at Austin Dell School of Medicine, Austin, TX
| | - Manesh R. Patel
- Division of Cardiology, Department of Medicine, Duke University Medical Center and Duke Clinical Research Institute, Durham, NC
| | - W. Schuyler Jones
- Division of Cardiology, Department of Medicine, Duke University Medical Center and Duke Clinical Research Institute, Durham, NC
| | - Renato D. Lopes
- Division of Cardiology, Department of Medicine, Duke University Medical Center and Duke Clinical Research Institute, Durham, NC
| | - Mandeep R. Mehra
- Brigham and Women’s Hospital Heart & Vascular Center and Harvard Medical School, Boston, MA
| | - Deepak L. Bhatt
- Brigham and Women’s Hospital Heart & Vascular Center and Harvard Medical School, Boston, MA
| | - Ajar Kochar
- Brigham and Women’s Hospital Heart & Vascular Center and Harvard Medical School, Boston, MA
| |
Collapse
|
6
|
Sharkawi MA, McMahon S, Al Jabri D, Thompson PD. Current perspectives on location of monitoring and length of stay following PPCI for ST elevation myocardial infarction. Eur Heart J Acute Cardiovasc Care 2019; 8:562-570. [PMID: 31264471 DOI: 10.1177/2048872619860217] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
IMPORTANCE There is marked variability in location of care and hospital length of stay after primary percutaneous coronary intervention for ST elevation myocardial infarction (STEMI). OBSERVATIONS We performed a literature review on non-critical care monitoring and early discharge following primary percutaneous coronary intervention and describe a framework for implementation in the real world. The medical literature was searched from 1 January 1988 to 31 April 2019 using PubMed and Cochrane Central Register of Controlled Trials. Randomized clinical trials, observational studies and guideline statements were included. Available data suggest that carefully selected low-risk STEMI patients identified using Zwolle or CADILLAC risk stratification scores after primary percutaneous coronary intervention may be considered for discharge after 48 hours of hospital care. There was no increase in major adverse cardiac events, medication non-compliance or hospital readmission with this treatment strategy. There are limited data on non-critical monitoring of uncomplicated STEMI patients; however, given the low adverse events rate, this strategy is likely to be safe in selected patients and may facilitate reduced length of stay and reduce resource utilization. CONCLUSIONS AND RELEVANCE Available evidence supports the safety of early discharge after 48 hours of care and omission of critical care monitoring in carefully selected patients following primary percutaneous coronary intervention. Early risk stratification and structured discharge planning are imperative. Adoption of this treatment strategy could reduce hospital costs, resource utilization and enhance patient satisfaction without affecting outcomes.
Collapse
Affiliation(s)
- Musa A Sharkawi
- Heart and Vascular Institute, Hartford HealthCare, USA.,University of Connecticut, School of Medicine, USA
| | - Sean McMahon
- Heart and Vascular Institute, Hartford HealthCare, USA.,University of Connecticut, School of Medicine, USA
| | | | - Paul D Thompson
- Heart and Vascular Institute, Hartford HealthCare, USA.,University of Connecticut, School of Medicine, USA
| |
Collapse
|
7
|
Sharkawi MA, Filippaios A, Dani SS, Shah SP, Riskalla N, Venesy DM, Labib SB, Resnic FS. Identifying patients for safe early hospital discharge following st elevation myocardial infarction. Catheter Cardiovasc Interv 2016; 89:1141-1146. [DOI: 10.1002/ccd.26873] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/21/2016] [Accepted: 11/06/2016] [Indexed: 12/14/2022]
Affiliation(s)
- Musa A. Sharkawi
- Department of Cardiovascular Medicine; Hartford Hospital; Hartford Connecticut
- University of Connecticut School of Medicine; Farmington Connecticut
| | - Andreas Filippaios
- Department of Internal Medicine; Lahey Hospital & Medical Center; Burlington Massachusetts
| | - Saurabh S. Dani
- Department of Cardiovascular Medicine; Lahey Hospital & Medical Center; Burlington Massachusetts
| | - Sachin P. Shah
- Department of Cardiovascular Medicine; Lahey Hospital & Medical Center; Burlington Massachusetts
- Tufts University School of Medicine; Boston Massachusetts
| | - Nabila Riskalla
- Department of Cardiovascular Medicine; Lahey Hospital & Medical Center; Burlington Massachusetts
| | - David M. Venesy
- Department of Cardiovascular Medicine; Lahey Hospital & Medical Center; Burlington Massachusetts
- Tufts University School of Medicine; Boston Massachusetts
| | - Sherif B. Labib
- Department of Cardiovascular Medicine; Lahey Hospital & Medical Center; Burlington Massachusetts
- Tufts University School of Medicine; Boston Massachusetts
| | - Frederic S. Resnic
- Department of Cardiovascular Medicine; Lahey Hospital & Medical Center; Burlington Massachusetts
- Tufts University School of Medicine; Boston Massachusetts
| |
Collapse
|
8
|
Khalifa MS, Sharkawi MA. Treatment of pain owing to acute ureteral obstruction with prostaglandin-synthetase inhibitor: a prospective randomized study. J Urol 1986; 136:393-5. [PMID: 3090274 DOI: 10.1016/s0022-5347(17)44878-6] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
Pain owing to acute ureteral obstruction seems to be related closely to tension in the walls of the renal pelvis. Renal prostaglandins are involved intimately in the events leading to the pain. A prostaglandin-synthetase inhibitor, diclofenac sodium, was used in the treatment of acute ureteral pain, and was compared to the traditional treatment of a combination of spasmolytic and narcotic drugs. Also, the need for overhydration as part of the management was tested. The 91 patients entered into the prospective randomized trial were divided into groups. Diclofenac sodium had a 90 per cent success rate in relieving pain at 30 minutes, and the combination of pethidine and hyoscine butyl bromide had a statistically higher success rate at 97.5 per cent (p equals 0.05). However, the latter therapy had a higher rate of side effects (p equals 0.01). There was no difference in the response between the groups in relation to whether they received intravenous fluids.
Collapse
|
9
|
|